Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Biochem Mol Toxicol ; 36(1): e22946, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34747550

RESUMO

Doxorubicin (DOX) is a potent antitumor agent with a broad spectrum of activity; however, irreversible cardiotoxicity resulting from DOX treatment is a major issue that limits its therapeutic use. Sirtuins (SIRTs) play an essential role in several physiological and pathological processes including oxidative stress, apoptosis, and inflammation. It has been reported that SIRT1 and SIRT3 can act as a protective molecular against DOX-induced myocardial injury through targeting numerous signaling pathways. Several natural compounds (NCs), such as resveratrol, sesamin, and berberine, with antioxidative, anti-inflammation, and antiapoptotic effects were evaluated for their potential to suppress the cardiotoxicity induced by DOX via targeting SIRT1 and SIRT3. Numerous NCs exerted their therapeutic effects on DOX-mediated cardiac damage via targeting different signaling pathways, including SIRT1/LKB1/AMPK, SIRT1/PGC-1α, SIRT1/NLRP3, and SIRT3/FoxO. SIRT3 also ameliorates cardiotoxicity by enhancing mitochondrial fusion.


Assuntos
Berberina/uso terapêutico , Dioxóis/uso terapêutico , Doxorrubicina/efeitos adversos , Cardiopatias/enzimologia , Lignanas/uso terapêutico , Miocárdio/enzimologia , Sirtuína 1/metabolismo , Sirtuína 3/metabolismo , Animais , Cardiotoxicidade/tratamento farmacológico , Cardiotoxicidade/enzimologia , Doxorrubicina/farmacologia , Cardiopatias/induzido quimicamente , Cardiopatias/tratamento farmacológico , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...